| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/28/2007 | EP1757277A1 Oral preparations and process for production thereof |
| 02/28/2007 | EP1757275A1 Seamless capsule containing water-soluble active ingredient |
| 02/28/2007 | EP1757271A1 Solid pharmaceutical preparation with improved stability and process for producing the same |
| 02/28/2007 | EP1757269A2 Pulmonary formulation comprising silicon particles |
| 02/28/2007 | EP1757268A1 Dry-form composition for oral ingestion and gel-form composition for oral ingestion of type prepared at time of use |
| 02/28/2007 | EP1756575A2 Detection of methamphetamine group drugs |
| 02/28/2007 | EP1756318A2 Aptamer-toxin molecules and method for using same |
| 02/28/2007 | EP1756265A2 Soy peptone as a nitrogen source in preparing meningococcal conjugates |
| 02/28/2007 | EP1756166A1 Prostate cancer diagnosis and treatment |
| 02/28/2007 | EP1756165A2 Tissue-specific imaging and therapeutical agents targeting proteins expressed on lung endothelial cell surface |
| 02/28/2007 | EP1756133A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1 |
| 02/28/2007 | EP1756039A2 Compounds and compositions for delivering active agents |
| 02/28/2007 | EP1755686A2 Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface |
| 02/28/2007 | EP1755684A2 Albumin-binding conjugates comprising a fatty acid and peg |
| 02/28/2007 | EP1755683A2 Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof |
| 02/28/2007 | EP1755682A1 Solid pharmaceutical formulation |
| 02/28/2007 | EP1755673A2 Anti-il-9 antibody formulations and uses thereof |
| 02/28/2007 | EP1755672A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 02/28/2007 | EP1755666A1 Vaccine compositions comprising virosomes and a saponin adjuvant |
| 02/28/2007 | EP1755662A2 Combined meningococcal conjugates with common carrier protein |
| 02/28/2007 | EP1755653A2 Treatment methods utilizing albumin-binding proteins as targets |
| 02/28/2007 | EP1755650A2 A biomolecule-containing formulation of increased stability |
| 02/28/2007 | EP1755633A1 Oral delivery of peptide pharmaceutical compositions |
| 02/28/2007 | EP1755630A1 Pharmaceutical compositions from beard lichen (usnea barbata) and st. john's wort (hypericum perforatum) and their use |
| 02/28/2007 | EP1755624A2 Polycationic antimicrobial therapeutic |
| 02/28/2007 | EP1755575A2 Antifungal drug delivery |
| 02/28/2007 | EP1755568A1 Controlled release formulation for oral administration of metformin |
| 02/28/2007 | EP1755551A2 Dpi formulation containing sulfoalkyl ether cyclodextrin |
| 02/28/2007 | EP1689437B1 Erythropoietin solution formulation |
| 02/28/2007 | EP1675621B1 Pharmaceutical compositions of lavendustin |
| 02/28/2007 | EP1551375B1 Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant |
| 02/28/2007 | EP1513532B1 Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
| 02/28/2007 | EP1454928B1 Process for production of water-soluble (meth)acrylic polymers, water-soluble (meth)acrylic polymers, and use thereof |
| 02/28/2007 | EP1436002B1 Use of peptide vectors to improve the immune response to antigens |
| 02/28/2007 | EP1392666B1 Biologically active methylene blue derivatives |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1346041B1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 02/28/2007 | EP1335710B8 Soft capsules comprising a starch mixture having a reduced branching degree |
| 02/28/2007 | EP1296685B1 Sustained-release preparations of quinolone antibiotics and method for preparation thereof |
| 02/28/2007 | EP1212091B1 Polyoxyalkylene copolymers containing pourable liquid vehicles |
| 02/28/2007 | EP1189634B1 Treating prostate cancer with anti-erbb2 antibodies |
| 02/28/2007 | EP1178811B1 Electrolyte gels for maintaining hydration and rehydration |
| 02/28/2007 | EP1151756B1 Kit comprising polyacrylamide gel for forming a capsule in the tissue of a mammal organism and allogenic or xenogenous cells of an animal, method for therapy of oncological diseases and the diabetes mellitus |
| 02/28/2007 | EP1123313B1 Methods and compositions for the prevention and treatment of anemia |
| 02/28/2007 | EP1096937B9 Sustained release ranolazine formulations |
| 02/28/2007 | EP1024827B1 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 02/28/2007 | EP0909323B1 Helicobacter pylori bacterioferritin |
| 02/28/2007 | CN1922199A Ca6 antigen-specific cytotoxic conjugate and methods of using the same |
| 02/28/2007 | CN1921891A Growth factor-binding compounds and methods of use |
| 02/28/2007 | CN1921890A Antibody linked cationic emulsions as drug delivery system |
| 02/28/2007 | CN1921889A Targeted immunogens |
| 02/28/2007 | CN1921888A Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same |
| 02/28/2007 | CN1921887A Soft capsule preparation |
| 02/28/2007 | CN1921880A Protein drug sustained-release microparticle preparation for injection and process for producing the same |
| 02/28/2007 | CN1921834A Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| 02/28/2007 | CN1921833A Alginate viscoelastic composition, method of use and package |
| 02/28/2007 | CN1921832A Dissolvable film and method of manufacture |
| 02/28/2007 | CN1921831A Dissolvable film comprising an active ingredient and method of manufacture |
| 02/28/2007 | CN1921830A Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| 02/28/2007 | CN1919908A Dissolvable film |
| 02/28/2007 | CN1919846A Novel oriented synthesis method of voriconazole, medicinal salt and intermediate thereof |
| 02/28/2007 | CN1919339A Cucurbitacin nano preparation comprising protein, preparation method and use thereof |
| 02/28/2007 | CN1919336A Method for preparing high activity long-acting PEG-interferon position isomer hybrid medicine |
| 02/28/2007 | CN1919214A Monascus soft capsule and its preparation method |
| 02/28/2007 | CN1919210A System for the liberation of an active principle and its use |
| 02/28/2007 | CN1919194A Liquid composition of sirolimus |
| 02/28/2007 | CN1919192A Curcumenol self-emulsifying capsule and preparation method thereof |
| 02/28/2007 | CN1919190A Composite intravenous injection emulsion of paclitaxel and traditional medicine volatile oil and its preparation process |
| 02/28/2007 | CN1919186A Tacrolimus oral administration preparation |
| 02/28/2007 | CN1919183A Pilocarpine nitrate dispersible tablet and preparation method thereof |
| 02/28/2007 | CN1919182A Mucosal delivery tablet |
| 02/28/2007 | CN1919181A Amphipathic fluorescence target nano micelle and its preparation method |
| 02/28/2007 | CN1919180A Anticancer slow release agent of nimustine and its progression agent |
| 02/28/2007 | CN1919179A Anticancer slow release preparation of nimustine and its progression agent |
| 02/28/2007 | CN1919178A Nimustine slow release injection for treating noumenal tumour |
| 02/28/2007 | CN1919177A Nimustine slow release agent for treating noumenal tumour |
| 02/28/2007 | CN1919176A Anticancer slow release agent of nimustine and its progression agent |
| 02/28/2007 | CN1919175A Medicinal composition of nimustine and its progression agent |
| 02/28/2007 | CN1919174A Anticancer slow release agent of nimustine and its progression agent |
| 02/28/2007 | CN1919173A Nimustine slow release injection for treating extracranial noumenal tumour |
| 02/28/2007 | CN1919172A Anticancer slow release agent of nimustine and its progression agent |
| 02/28/2007 | CN1302115C Buffer solution for electroporation and a method comprising the use of the same |
| 02/28/2007 | CN1302050C Interpenetrating network polymer type super porous aquogel, its prepn. method and application |
| 02/28/2007 | CN1302041C Cationic alkgd polyester capable for medical application |
| 02/28/2007 | CN1301993C Dimeric compounds and their use as anti-viral agents |
| 02/28/2007 | CN1301963C Process for producing N-(4-fluobenzene radical)-N-(2-hydroxy-4-chlorobenzene group) glycocoll |
| 02/28/2007 | CN1301750C Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy |
| 02/28/2007 | CN1301748C Antineoplastic nanometer heat sensitive target medicine carrier used combined with chemical therapy and heat therapy |
| 02/28/2007 | CN1301706C Pharmaceutical composition for sustained or continuous releasing therapeutic active components |
| 02/27/2007 | USRE39497 Storage of materials |
| 02/27/2007 | US7183392 Site-specific, covalent bioconjugation of proteins |
| 02/27/2007 | US7183319 Phenylethylamine derivatives and their use in the treatment of melanoma |
| 02/27/2007 | US7183266 Dual induced viscosity fiber system and uses thereof |
| 02/27/2007 | US7183263 protein expression levels higher than linear polyethylenimine alone, and twice that of branched polyethylenimine, but without any significant loss in cell viability; sterols such as cholesterol conjugated via the haloformate ester reaction |
| 02/27/2007 | US7183259 Amino acid conjugates providing for sustained systemic concentrations of GABA analogues |
| 02/27/2007 | US7183111 Immunomodulatory formulations and methods for use thereof |
| 02/27/2007 | US7182965 pollen polyterpenes for the treatment of microbial, especially bacterial, diseases for topical, oral and parenteral administration in humans and animals |
| 02/27/2007 | US7182964 Dissolving thin film xanthone supplement |
| 02/27/2007 | US7182961 Particulate compositions for pulmonary delivery |
| 02/27/2007 | US7182960 Pharmaceutical compositions for nasal delivery of oestradiol and norethisterone |